Pausing biologics for covid boosters: no antibody gain, double the flare risk

The advice has circulated long enough that it has started to feel like established fact: if you are on a biologic or a JAK inhibitor and a covid booster is due, hold the medication for a couple of weeks to let your immune system respond properly. It is a plausible-sounding recommendation. The immune logic seems to follow.

The problem is that the first randomised trial to test it directly has found the logic was wrong. Pausing these medications does not improve the antibody response. It does, however, meaningfully increase the chance of an inflammatory disease flare.

What the COVER trial tested

The COVER trial enrolled 840 patients with inflammatory arthritis — rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis — from 29 rheumatology practices across the United States. All had completed a primary covid vaccination series and were being managed on TNF inhibitors, IL-17 inhibitors, abatacept, or JAK inhibitors. The trial ran from November 2021 to May 2024.

Participants were randomised to either continue their treatment through a supplemental covid booster, or hold it for two weeks after the booster. The primary question was straightforward: does pausing produce a better antibody response?

The answer, published in JAMA Internal Medicine in October 2026, was no.

The numbers that matter

The primary outcome was change in anti-RBD IgG antibodies from baseline to six weeks. The adjusted geometric mean fold rise was 4.69 in the hold group and 4.86 in the continue group — a ratio of 0.96 (95% CI 0.36–2.56). That confidence interval tells the whole story: the data is compatible with a wide range of outcomes centred on no difference at all.

The harm was not ambiguous. Pausing medication more than doubled the odds of an inflammatory flare or disease worsening (OR 2.27; 95% CI 1.41–3.65). For those on JAK inhibitors, the odds were tripled (OR 3.65; 95% CI 1.69–7.87).

The timing of that worsening matters. At a median of 10 days post-booster — while patients in the hold group were still off their treatment — 21.1% reported clinically meaningful worsening compared with 9.1% of the continue group. That is a 12 percentage-point difference (95% CI 5.9–18.1 points) in the window when the pause was supposed to be doing its immunological work. The hold group also reported more muscle aches, more joint pain, and more new or worsening fatigue (30% vs 19%) during that period.

By six weeks, both groups had returned to similar disease activity levels. The flare largely resolved. But the hold group had spent those two weeks worse off, with no immunological return on the cost.

Both-and: what this study establishes and what it does not

The original rationale for pausing was grounded in real biology. Immunosuppressants can blunt vaccine responses — this has been documented in observational studies, and the mechanism is plausible. The question the COVER trial was designed to answer was whether the blunting is clinically meaningful enough to justify disrupting treatment.

The answer for a two-week hold after a covid booster, in this patient population, is no. The researchers’ stated conclusion: “these findings do not support routine temporary interruption for Covid-19 vaccine optimisation.”

There are limitations worth holding. About 31% of participants had missing outcome data. The design was open-label, which can affect how patients report symptoms. Critically, a two-week pause is likely shorter than the effective window for longer-acting biologics — rituximab, for instance, has a pharmacological duration that extends well beyond two weeks. So it remains possible that a longer interruption would show an antibody benefit not captured here.

What the trial does not address is cellular immunity. Anti-RBD IgG antibodies are a measurable proxy for vaccine response, but T-cell responses and clinical protection from severe covid were not assessed. It is theoretically possible to have equivalent antibodies and different T-cell responses, though the trial was not designed to detect this.

These limitations do not change the practical conclusion for the most common scenario: a person with RA or psoriatic arthritis on a standard biologic or JAK inhibitor, getting a covid booster. For that situation, the trial’s message is clear.

What this means for people on these medications in Australia

Around 500,000 Australians live with inflammatory arthritis, and a significant proportion are managed on biologic therapies or JAK inhibitors — medications that have transformed outcomes for these conditions over the past two decades. These are also people who are more vulnerable to severe covid outcomes, which makes getting boosters more important, not less.

The Medical Republic covered the COVER results on 29 October 2026, noting that the article carries implications for how rheumatologists and GPs counsel patients around vaccine timing.

The practical question in a GP consultation is usually framed as: “Do I need to stop my medication before the vaccine?” Based on COVER, the default answer for covid boosters is no — continuing treatment through the vaccination is associated with equivalent antibody responses and substantially lower flare risk.

This is worth discussing with the doctor managing your arthritis before your next booster, particularly if you have been pausing medications around past vaccinations. Individual circumstances still matter: an upcoming surgery, a switch to a different agent, or other clinical considerations may shift the timing. But the trial does not support pausing as a default strategy for vaccine optimisation.

2 cents

The finding effectively reverses a reasonable-seeming instinct: pause the immunosuppressant, let the immune system work, get a better response. That instinct turned out to be wrong, at least for the agents tested and the two-week pause window studied.

For the many Australians on biologics or JAK inhibitors, the message is worth knowing: getting a covid booster on your regular treatment schedule is the safer approach. The pause causes real harm — a meaningful proportion of patients spent those two weeks in a flare — and does not appear to deliver the intended benefit.

If you have been holding medications around covid vaccinations, bring this to your next appointment with the doctor or specialist who manages your arthritis.

Verdict: yes — worth knowing about.

---

Sources cited

1. Holding biologics and JAKi for covid boosters doesn’t help — The Medical Republic, 29 October 2026
2. Effect of Temporary Interruption of Biologic or JAK Inhibitor Therapy on SARS-CoV-2 Vaccine Response — JAMA Internal Medicine, October 2026